Nokia and Ooredoo Group sign strategic 5-year agreement, including 5G
Nokia and Ooredoo Group sign strategic 5-year agreement, including 5G
- Multi-country deal across Middle East, North Africa and South-east Asia cover multiple technologies including RAN, Core, Optics, IP and microwave
29 November 2021
Espoo, Finland – Nokia today announced that it has been selected by Ooredoo Group to bring multiple technologies and services, including 5G, to customers in Middle East, North Africa and South-east Asia as part of a multi-country, five-year deal. The deal, which builds on Nokia’s global partnership with Ooredoo, will see Nokia expand Ooredoo’s existing network, as well as introduce new 5G services. The deployment is already underway and is expected to be completed by 2026 in all these countries.
Under the deal, Nokia will deploy equipment from its latest AirScale RAN portfolio on sites across North Africa and Southeast Asia. Nokia’s AirScale radio platform features the flexibility and capability required for delivering 5G services to consumers and enterprises across different spectrum bands. The deal also includes digital deployment services supporting a faster time to market as well as technical support services.
Nokia will also provide its cloud-native Core software to give Ooredoo zero-touch automation capabilities that will drive greater scale and reliability. Supported by Nokia Cloud Packet Core, Voice Core, Registers, Policy Controller, Signaling and Cloud Platform, Ooredoo will be able to introduce network slicing to launch and grow new services spanning health, smart cities, banking, transportation, and public safety more rapidly.
Nokia’s optical solutions will ensure expansion and applications flow for Ooredoo’s state-of-the-art optical network without constraint. This provides increased network flexibility and operational automation through zero-touch transparent photonic networking.
Nokia’s microwave transport supports 5G microwave growth and new spectrum like E-band. The transport networks will enable seamless launching of new services where communities and businesses can rely on privacy, security, and near instant response times.
Aziz AluthmanFakhroo, Managing Director, Ooredoo Group, said: “This renewed contract is testimony to our growing partnership with Nokia to modernize and expand our network by rolling out world-class 4G and 5G services across North Africa and Southeast Asia. Thanks to Nokia’s advanced technology, our customers will be able to experience faster speeds and enhanced response times as well as more bandwidth.”
Pekka Lundmark, President and Chief Executive Officer at Nokia, said: “We are excited to continue delivering robust networks to Ooredoo’s customers. This new five-year deal will accelerate the benefits of Nokia’s technology – including 5G – for consumers in Middle East, North Africa and Southeast Asia and will enable businesses to digitalize and innovate with new services. The move to 5G will drive radical transformation across industries, communities and public services and we are proud to continue supporting Ooredoo Group on this journey.”
Video: Nokia and Ooredoo Group dignitaries at the agreement signing ceremony in Ooredoo Headquarters in Doha, Qatar
Photos: See photos as attachments at the end of the release.
Photo 1: Left to right -- Aziz Aluthman Fakhroo, Managing Director, Ooredoo Group; and Pekka Lundmark, President and Chief Executive Officer at Nokia
Photo 2 (Group): Nokia and Ooredoo Group dignitaries at the agreement signing ceremony in Ooredoo Headquarters in Doha, Qatar
- Nokia AirScale
- Nokia 5G
- Nokia 5G Core
- Nokia Cloud Packet Core
- Nokia Voice Core
- Nokia Registers
- Nokia Policy Controller
- Nokia Cloud PlatformNokia Optical Networks
At Nokia, we create technology that helps the world act together.
As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs.
Adhering to the highest standards of integrity and security, we help build the capabilities needed for a more productive, sustainable and inclusive world.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Verisk Welcomes Olumide Soroye to Its Board of Directors18.8.2022 22:15:00 CEST | Press release
JERSEY CITY, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK) today announced that Olumide Soroye has been appointed independent director of the company’s Board of Directors effective immediately. Soroye brings three decades of leadership experience across multiple industries. “Olumide’s experience in software, data analytics, AI, and growth-minded leadership make him an exceptional addition to Verisk’s board,” Verisk CEO Lee Shavel said. “We look forward to working closely with Olumide to ensure that we continue to drive value and positive impact for all Verisk stakeholders including shareholders, clients, employees and partners.” Soroye, 50, is president and chief executive officer of Fortive Corporation’s Intelligent Operating Solutions segment. Before Fortive, he held leadership roles at CoreLogic, where he was managing director of property intelligence & risk management, and QuinStreet, where he was senior vice president of the company’s technology and home services b
Galapagos receives transparency notification from FMR LLC18.8.2022 22:01:00 CEST | Press release
Mechelen, Belgium;18 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 15 August 2022 from FMR LLC, who notified that it holds 3,740,842 of Galapagos’ voting rights, consisting of 3,740,842 ordinary shares. FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,303,128 voting rights, and no longer holds any equivalent financial instruments, and Strategic Advisers LLC decreased its position to 10,082 voting rights. FMR LLC's holding of 3,740,842 Galapagos' voting rights represents 5.69% of Galapagos' currently outstanding 65,728,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights considering the
Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines18.8.2022 20:24:11 CEST | Press release
U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.Agreement will significantly expand Bavarian Nordic’s manufacturing capacity for the benefit of the U.S. and globallyExpedited tech transfer has already started, allowing for manufacturing of first doses in 2022 COPENHAGEN, Denmark, August 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a U.S. based contract manufacturer, for fill and finish of JYNNEOS smallpox/monkeypox vaccine. As announced on July 15, 2022, Bavarian Nordic received an additional order for 2.5 million doses the vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR), which will be filled at GRAM using bulk vaccine already ma
Bavarian Nordic udvider produktionskapaciteten via aftale med amerikansk kontraktproducent om fyldning af koppe-/abekoppevacciner18.8.2022 20:24:11 CEST | pressemeddelelse
Den FDA-godkendte kontraktproducent, Grand River Aseptic Manufacturing, vil bistå med fyldning af allerede produceret råvaccine med henblik på at fremskynde leverancer af abekoppevacciner til USAAftalen vil øge Bavarian Nordics produktionskapacitet markant til gavn for både USA og lamde globaltEn accelereret procesoverførsel er allerede startet, hvilket muliggør produktion af de første doser i 2022 KØBENHAVN, Danmark, 18. august 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en aftale med den amerikanske kontraktproducent Grand River Aseptic Manufacturing (GRAM) om fyldning af JYNNEOS koppe-/abekoppevaccine. Som meddelt den 15. juli 2022, modtog Bavarian Nordic en yderligere ordre på 2,5 mio. doser af vaccinen fra U.S. Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR), som vil blive påfyldt på GRAMs facilitet ved brug af den råvaccine, der allerede er fremstillet og fa
PCI Biotech: Company update18.8.2022 18:05:06 CEST | Press release
Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward. As PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology a reduction of the clinical team will be enacted during the second half of 2022. Further details about the development plans for the non-clinical assets will be given at the upcoming Q2 reporting, scheduled 31st August 2022. The cash position per Q2 2022 is around NOK 76 million and the financial runway is estimated to be towards the end of 2023. Contact information: Ronny Skuggedal, Interim CEO firstname.lastname@example.org Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisatio